Medifast Inc (NYSE:MED) – Research analysts at DA Davidson upped their Q1 2018 earnings per share estimates for Medifast in a note issued to investors on Thursday. DA Davidson analyst L. Weiser now forecasts that the specialty retailer will post earnings of $0.61 per share for the quarter, up from their previous estimate of $0.60. DA Davidson currently has a “Buy” rating and a $89.00 target price on the stock. DA Davidson also issued estimates for Medifast’s Q3 2018 earnings at $0.67 EPS, FY2018 earnings at $2.60 EPS and FY2019 earnings at $3.26 EPS.

Medifast (NYSE:MED) last released its quarterly earnings results on Tuesday, November 7th. The specialty retailer reported $0.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.04. Medifast had a return on equity of 24.07% and a net margin of 8.58%. The company had revenue of $77.20 million during the quarter, compared to analyst estimates of $74.94 million. During the same quarter last year, the business posted $0.51 earnings per share. The firm’s revenue was up 12.5% on a year-over-year basis.

MED has been the topic of several other reports. Zacks Investment Research upgraded shares of Medifast from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a research note on Friday, November 10th. ValuEngine lowered shares of Medifast from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Sidoti restated a “neutral” rating and issued a $55.00 price objective (up from $49.00) on shares of Medifast in a research note on Thursday, September 21st. Finally, BidaskClub upgraded shares of Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $74.33.

Medifast (NYSE MED) traded up $0.34 during mid-day trading on Monday, reaching $73.22. 327,200 shares of the company’s stock were exchanged, compared to its average volume of 98,398. The firm has a market cap of $869.72, a P/E ratio of 35.90, a price-to-earnings-growth ratio of 2.24 and a beta of 0.51. Medifast has a 12 month low of $39.97 and a 12 month high of $73.60.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 8th. Stockholders of record on Friday, December 22nd will be issued a $0.48 dividend. This is an increase from Medifast’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, December 21st. This represents a $1.92 annualized dividend and a dividend yield of 2.62%. Medifast’s payout ratio is presently 63.05%.

In other Medifast news, Director Glenn W. Welling sold 250,000 shares of Medifast stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.00, for a total transaction of $16,250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glenn W. Welling sold 275,000 shares of Medifast stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $64.60, for a total transaction of $17,765,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 550,000 shares of company stock worth $34,019,500. Insiders own 5.40% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. American Century Companies Inc. raised its holdings in Medifast by 60.8% during the 3rd quarter. American Century Companies Inc. now owns 301,115 shares of the specialty retailer’s stock worth $17,877,000 after purchasing an additional 113,885 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Medifast by 217.1% in the third quarter. JPMorgan Chase & Co. now owns 158,813 shares of the specialty retailer’s stock valued at $9,468,000 after buying an additional 108,736 shares during the period. Marshall Wace North America L.P. raised its stake in shares of Medifast by 356.6% in the second quarter. Marshall Wace North America L.P. now owns 103,812 shares of the specialty retailer’s stock valued at $4,256,000 after buying an additional 81,075 shares during the period. Principal Financial Group Inc. raised its stake in shares of Medifast by 81.7% in the third quarter. Principal Financial Group Inc. now owns 166,311 shares of the specialty retailer’s stock valued at $9,874,000 after buying an additional 74,802 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Medifast by 197.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 89,606 shares of the specialty retailer’s stock valued at $3,716,000 after purchasing an additional 59,437 shares during the period. Institutional investors own 86.91% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Q1 2018 EPS Estimates for Medifast Inc Lifted by DA Davidson (MED)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/12/q1-2018-eps-estimates-for-medifast-inc-lifted-by-da-davidson-med.html.

Medifast Company Profile

Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.

Earnings History and Estimates for Medifast (NYSE:MED)

Receive News & Stock Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related stocks with our FREE daily email newsletter.